FDA’s Breakthrough Designation Granted for Kaposi Sarcoma Therapy – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Celgene’s pomalidomide (Pomalyst) has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with previously-treated HIV-positive Kaposi sarcoma (KS) and patients with HIV-negative KS, according to a press release.
KS is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels. The disease most commonly affects individuals with HIV, for whom there are currently no approved therapies in the refractory or chemotherapy-intolerant setting.
Pomalidomide, a thalidomide analogue, is currently indicated in combination with dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, and who have demonstrated disease progression on or within 60 days of completion of the last therapy.